flutiform® pMDI has a similar tolerability profile to fluticasone propionate/ salmeterol pMDI†2 and budesonide/ formoterol DPI.‡3
*Open-label study: Patients ≥12 years treated with flutiform® pMDI 50/5 μg or 125/5 μg two puffs b.i.d for 6 or 12 months.1
†Randomised, open-label, 12-week study in patients ≥18 years (flutiform® pMDI 50/5 μg or 125/5 μg two puffs b.i.d. vs fluticasone propionate/ salmeterol pMDI 50/25 μg or 125/25 μg two puffs b.i.d).2
‡Randomised, double-blind, double-dummy 12-week study (flutiform® pMDI 125/5 μg two puffs b.i.d. vs budesonide/ formoterol 200/6 μg two puffs b.i.d).3
Abbreviations: b.i.d, twice-daily; DPI, dry powder inhaler; pMDI, pressurised metered-dose inhaler
Safety Profile4
Adverse events which have been associated with flutiform® pMDI during clinical development, listed by system organ class, are available in the flutiform® Prescribing Information. None of the adverse events have been classed as very common (1/10) or common (≥1/100 and <1/10).
Abbreviation: pMDI, pressurised metered-dose inhaler
References
- Mansur AH, et al. J Aerosol Med Pulm Drug Deliv. 2012:26(4):190-199.
- Bodzenta-Lukaszyk A, et al. BMC Pulm Med. 2011;11:28.
- Bodzenta-Lukaszyk A, et al. J Asthma. 2012;49:1060-1070.
- flutiform® SmPC. Last updated 13 April 2022. https://www.emcpi.com/pi/26954. Accessed 5 September 2022.
Join our mailing list!
Join your colleagues and sign up for the latest news on the management of asthma and flutiform® pMDI straight to your inbox.
Abbreviation: pMDI: pressurised metered-dose inhaler
®: FLUTIFORM is the Trademark of Jagotec AG used under licence by Mundipharma.
®: The ‘lung’ logo, is a Registered Trademark of Mundipharma.